Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine

Gastroenterology

Volumn 147, Issue 1, 2014, Pages 152-161

  Lim, Young Suk ^a   Han, Seungbong ^a   Heo, Nae Yun ^b   Shim, Ju Hyun ^a   Lee, Han Chu ^a   Suh, Dong Jin ^a  

^a Asan Medical Center   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Comparative Effectiveness; HBV; Liver Cancer; Survival

Indexed keywords

ALBUMIN; ENTECAVIR; LAMIVUDINE;

ADULT; ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURGICAL RISK; THROMBOCYTE; TREATMENT DURATION;

COMPARATIVE EFFECTIVENESS; HBV; LIVER CANCER; SURVIVAL;

ADULT; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; LAMIVUDINE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84903185561     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.02.033     Document Type: Article

References (45)

1. J.F. Perz, G.L. Armstrong, and L.A. Farrington et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538
2. E.R. Schiff Prevention of mortality from hepatitis B and hepatitis C Lancet 368 2006 896 897
3. Y.F. Liaw, J.J. Sung, and W.C. Chow et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
4. J.R. Eun, H.J. Lee, and T.N. Kim et al. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease J Hepatol 53 2010 118 125
5. G.V. Papatheodoridis, E. Dimou, and K. Dimakopoulos et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine Hepatology 42 2005 121 129
6. M.F. Yuen, W.K. Seto, and D.H. Chow et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antivir Ther 12 2007 1295 1303
7. T.T. Chang, R.G. Gish, and R. de Man et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
8. T.T. Chang, C.L. Lai, and S.K. Yoon et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B Hepatology 51 2010 422 430
9. P. Marcellin, E.J. Heathcote, and M. Buti et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
10. K.M. Kitrinos, A. Corsa, and Y. Liu et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B Hepatology 59 2014 434 442
11. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
12. Korean Association for the Study of the Liver KASL Clinical Practice Guidelines: management of chronic hepatitis B Clin Mol Hepatol 18 2012 109 162
13. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
14. H.J. Seo, I.H. Oh, and S.J. Yoon A comparison of the cancer incidence rates between the National Cancer Registry and insurance claims data in Korea Asian Pac J Cancer Prev 13 2012 6163 6168
15. B.C. Song, D.J. Suh, and H.C. Lee et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 2000 803 806
16. G.L. Wong, H.L. Chan, and H.Y. Chan et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment Gastroenterology 144 2013 933 944
17. V.W. Wong, S.L. Chan, and F. Mo et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers J Clin Oncol 28 2010 1660 1665
18. M.F. Yuen, Y. Tanaka, and D.Y. Fong et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B J Hepatol 50 2009 80 88
19. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
20. J. Saldanha, W. Gerlich, and N. Lelie et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques Vox Sang 80 2001 63 71
21. H. Kim, Y.M. Jee, and B.C. Song et al. Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea Intervirology 50 2007 52 57
22. S.P. Hong, N.K. Kim, and S.G. Hwang et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments J Hepatol 40 2004 837 844
23. R.H. Fletcher, and S.W. Fletcher Clinical epidemiology: the essentials 2005 Lippincott Williams & Wilkins Philadelphia, PA
24. M.S. Cepeda, R. Boston, and J.T. Farrar et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders Am J Epidemiol 158 2003 280 287
25. B.H. Hamilton, C.Y. Ko, and K. Richards et al. Missing data in the American College of Surgeons National Surgical Quality Improvement Program are not missing at random: implications and potential impact on quality assessments J Am Coll Surg 210 2010 125 139
26. T.M. Therneau, and P.M. Grambsch Modeling survival data: extending the Cox model 2000 Springer New York, NY
27. J.P. Klein, and M.L. Moeschberger Survival analysis: techniques for censored and truncated data 2003 Springer New York, NY
28. E.A. Stuart Matching methods for causal inference: a review and a look forward Stat Sci 25 2010 1 21
29. T. Hosaka, F. Suzuki, and M. Kobayashi et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 2013 98 107
30. G.L. Wong, H.L. Chan, and C.W. Mak et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis Hepatology 58 2013 1537 1547
31. S.C. Gordon, L.E. Lamerato, and L.B. Rupp et al. Antiviral Therapy for Chronic Hepatitis B Virus Infection and Development of Hepatocellular Carcinoma in a US Population Clin Gastroenterol Hepatol 12 2014 885 893
32. C.Y. Wu, J.T. Lin, and H.J. Ho et al. Association of Nucleos(t)ide Analogue Therapy with Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B - a Nationwide Cohort Study Gastroenterology 147 2014 143 151
33. A.K. Singal, H. Salameh, and Y.F. Kuo et al. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B Aliment Pharmacol Ther 38 2013 98 106
34. C.L. Lai, D. Shouval, and A.S. Lok et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B N Engl J Med 354 2006 1011 1020
35. M. Levrero, T. Pollicino, and J. Petersen et al. Control of cccDNA function in hepatitis B virus infection J Hepatol 51 2009 581 592
36. C. Neuveut, Y. Wei, and M.A. Buendia Mechanisms of HBV-related hepatocarcinogenesis J Hepatol 52 2010 594 604
37. C. Brechot Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms Gastroenterology 127 2004 S56 S61
38. G.V. Papatheodoridis, P. Lampertico, and S. Manolakopoulos et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2010 348 356
39. Y. Hoshida, A. Villanueva, and M. Kobayashi et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 2008 1995 2004
40. European Association for the Study of the Liver EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 56 2012 908 943
41. T.T. Chang, Y.F. Liaw, and S.S. Wu et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 2010 886 893
42. P. Marcellin, E. Gane, and M. Buti et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
43. C.L. Lin, and J.H. Kao The clinical implications of hepatitis B virus genotype: recent advances J Gastroenterol Hepatol 26 Suppl 1 2011 123 130
44. K.A. McGlynn, and W.T. London The global epidemiology of hepatocellular carcinoma: present and future Clin Liver Dis 15 2011 223 243
45. Korean Liver Cancer Study Group National Cancer Center. Practice guidelines for management of hepatocellular carcinoma 2009 Korean J Hepatol 15 2009 391 423